HHS Deprescribing Push: No Payment, No Change in 12 Months

Source: https://x.com/i/status/2051815964488900833

Observation

On May 4, 2026, U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced a department‑wide plan to curb “overprescribing” of psychiatric medications, support tapering/discontinuation, and expand non‑medication options. The rollout paired a Substance Abuse and Mental Health Services Administration (SAMHSA) Dear Colleague letter, Centers for Medicare & Medicaid Services (CMS) guidance that HHS says clarifies how clinicians can be paid for deprescribing‑related care under Medicare, and a timeline: a prescribing‑trends report in May, webinars in June–July, and a Technical Expert Panel in July.

The question that matters: Will this mix of guidance, education, and CMS billing clarification materially reduce inappropriate long‑term use within 12 months? It’s debatable because payment, state Medicaid adoption, and professional‑society signals—not federal rhetoric—determine short‑run clinical behavior. Payers, provider strategy teams, and healthcare investors all have forecasts tied to drug utilization and care‑mix shifts.

Our call: If you are a healthcare equity PM or a health‑system strategy lead, hedge the “12‑month prescribing reduction” thesis. Defer major operational bets until CMS issues explicit code‑level payment language and watch for state Medicaid moves; assume only patchy impact otherwise.

Policy & Legal Structure

A reasonable pushback is that an HHS‑wide initiative should be enough to move practice. The structure says otherwise. SAMHSA’s Dear Colleague letter is soft law: it shapes norms, not reimbursement. Education and webinars only travel as far as clinician time allows. What unlocks time‑intensive deprescribing is a billable pathway with clear codes and rates under the Medicare Physician Fee Schedule (PFS)—or explicit language in a Medicare Learning Network (MLN) Matters article naming which existing codes, and their relative value units (RVUs), apply to deprescribing work. CMS has issued guidance, but without code‑level clarity in MLN/PFS materials, documentation can improve without meaningful changes in prescribing.

The department’s timeline reinforces the constraint. The Technical Expert Panel convenes in July to inform formal guidance; that sequence pushes any binding clinical protocols into late 2026 at best. In parallel, state Medicaid programs are the operative venues for many children and low‑income adults. Some, like Texas or Utah, can turn federal signals into utilization management (UM) rules or reimbursed services quickly via State Plan Amendments (SPAs); others will wait. That heterogeneity yields localized pilots, not a national step‑change, over a 12‑month window.

Professional societies are the third gate. If the American Psychiatric Association (APA) translates its initial supportive‑but‑cautious stance into formal taper guidance and member toolkits, payer and provider confidence rises; if suicide‑prevention groups like the American Foundation for Suicide Prevention (AFSP) press for stronger safeguards absent expanded therapy access, rollouts slow. In plain terms: CMS payment policy is the key constraint; SAMHSA guidance is a non‑binding venue; state Medicaid bulletins are the transmission channels; and APA/AFSP hold normative authority that can accelerate or dampen uptake. Absent a decisive CMS move, the rest of the stack does not carry enough force to measurably shift long‑term prescribing in 12 months.

Nine Star Ki Reading

Read CMS as an agency in motion—an actor taking concrete steps like issuing MLN/PFS guidance or standing up billing rules. Through that lens, CMS maps to Two Black Earth (Jikoku Dosei, 二黒土星), associated here with “preparation.”

The underlying nature is procedural and consultative—methodical planning and stakeholder coordination. What is showing now is the same nature, but on the surface: grounded, administrative work to line up billing language and document workflows. That alignment signals we are still in preparation rather than decisive change; it supports the payment‑gate thesis above.

In the cycle, CMS sits at 艮宮 (Gen, “mountain”), where internal setup and consolidation dominate. The next move is toward 震宮 (Shin, “thunder”), where the work turns outward—announcements, implementation, and signal amplification. That trajectory suggests near‑term documents are plausible, but not yet the kind of enforceable payment change that would guarantee a measurable utilization response within a year.

Recommendations

If you are a healthcare equity PM or a health‑system strategy lead, run a hedge: keep national prescribing‑reduction expectations muted in 12‑month models unless CMS names codes and rates in MLN/PFS materials. Allocate attention to state Medicaid early movers and Medicare Advantage pilots; treat SAMHSA’s report as the baseline‑definition document that will shape metrics, not behavior, this quarter.

• CMS MLN/PFS payment clarity: by June 30, 2026, at least one MLN Matters article or PFS update explicitly names a new Current Procedural Terminology (CPT) or Healthcare Common Procedure Coding System (HCPCS) code, or lists existing codes billable for deprescribing (threshold = 1; horizon: 2–8 weeks).
• SAMHSA prescribing‑trends report: by May 31, 2026, includes at least one operational definition with a numeric cutoff for “long‑term use” (e.g., ≥6 or ≥12 months) and baseline rates by drug class/age (threshold = presence of numeric definition and baselines; horizon: May).
• State Medicaid adoption: by August 31, 2026, three or more states issue bulletins or SPAs creating reimbursable deprescribing services or new psychotropic UM tied to alternatives (threshold = 3 states; horizon: 1–3 months).
• APA guidance: by July 31, 2026, one formal APA practice product endorses taper protocols with member toolkits (threshold = 1 product; horizon: 2–8 weeks).

Caveats and Open Questions

• CMS could post a definitive MLN/PFS update creating a distinct billing pathway—new CPT/HCPCS or explicit PFS coding rules—for deprescribing. If that appears, the hedge fails and a 12‑month impact becomes credible.
• The American Psychiatric Association could quickly publish formal guidance and toolkits endorsing HHS protocols. That would lower implementation friction and prompt payer alignment faster than expected.
• A major state Medicaid program (e.g., Texas HHSC) could issue a bulletin funding deprescribing services or tightening psychotropic UM with concurrent therapy coverage, driving measurable regional reductions that outpace Medicare.

Lead‑time question: Will CMS publish an MLN Matters/PFS update explicitly naming billable deprescribing codes by June 30, 2026—or are you positioned for another quarter of preparation without payment?